Drug intelligence / Profile preview

SCAI-001

Development stage: Phase 2
Lead developer: SCAI Therapeutics
Modality: Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Ophthalmic, Oral, Intravenous, Topical

Overview

SCAI-001 is an investigational ophthalmic formulation of cyclosporine A, developed as eye drops at concentrations of 0.01% and 0.02%. It is being evaluated for the treatment of dry eye disease (DED). Cyclosporine A acts as a calcineurin inhibitor, suppressing T-cell activation and reducing ocular surface inflammation associated with DED. SCAI-001 has been compared to Restasis (cyclosporine 0.05%) in clinical trials to assess its safety and efficacy in patients with dry eye disease[1][5][6].

Other names: cyclosporine A (SCAI-001)

Targets

CN (Calcineurin)

Beyond the preview

Go deeper on SCAI-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCAI-001.